BAD and liver cancer: The findings demonstrated that SS-b2 exerts an anticarcinogenic effect on the HepG2 liver cancer cells, resulting in a reduction in the expression of the antiapoptotic protein Bcl-2 and an increase in the expression of the proapoptotic protein BAD.